[Management of non-small cell lung cancer patients harboring activating mutations and CNS progression].
Caractéristiques et prise en charge de l’évolutivité cérébro-méningée des cancers bronchiques dans un contexte de mutation activatrice.
Adult
Aged
Aged, 80 and over
Anaplastic Lymphoma Kinase
/ genetics
Carcinoma, Non-Small-Cell Lung
/ genetics
Central Nervous System Neoplasms
/ genetics
Disease Progression
ErbB Receptors
/ genetics
Female
Gain of Function Mutation
Humans
Lung Neoplasms
/ genetics
Male
Middle Aged
Proto-Oncogene Proteins B-raf
/ genetics
Receptor, ErbB-2
/ genetics
Retrospective Studies
ALK
Cancer bronchique
Cerebral metastases
EGFR cancer
EGFR lung meningitis targeted therapy
Méningite carcinomateuse
Métastases cérébrales
Journal
Revue des maladies respiratoires
ISSN: 1776-2588
Titre abrégé: Rev Mal Respir
Pays: France
ID NLM: 8408032
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
12
12
2016
accepted:
16
03
2019
pubmed:
17
6
2019
medline:
16
1
2020
entrez:
17
6
2019
Statut:
ppublish
Résumé
The central nervous system (CNS), through carcinomatous meningitis or solid brain metastases, is the most common site of recurrence in non-small cell lung cancers (NSCLC) with activating mutations. Our retrospective study describes the population of patients with CNS metastases of NSCLC harboring activating mutation with targeted therapy (EGFR, ALK, BRAF, HER2) in 4 French regional reference hospitals. 60 patients were analyzed. The proposed treatments were heterogeneous and included combinations of chemotherapy, targeted therapy and radiotherapy±associated with topical treatments. Median overall survival following CNS metastasis in these patients was 15.8 months for meningitis carcinoma and 26 months for brain metastases. In patients with brain metastases, the addition of targeted therapy treatment allows a significant improvement in median progression free survival from 5.9 months to 10.6 months (HR 0.48 CI95 [0.24 to 0.97] P=0.035). These patients seem therefore benefit from systemic therapy and particularly targeted therapy with better survival than usual.
Identifiants
pubmed: 31202602
pii: S0761-8425(19)30136-6
doi: 10.1016/j.rmr.2019.04.003
pii:
doi:
Substances chimiques
ALK protein, human
EC 2.7.10.1
Anaplastic Lymphoma Kinase
EC 2.7.10.1
EGFR protein, human
EC 2.7.10.1
ERBB2 protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
fre
Sous-ensembles de citation
IM
Pagination
583-590Informations de copyright
Copyright © 2019 SPLF. Published by Elsevier Masson SAS. All rights reserved.